XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 260.10K | 621.90K | 495.10K | 393.00K | 476.00K |
| Depreciation & Amortization | 18.30K | 25.80K | 29.10K | 29.40K | 27.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 392.40K | 680.90K | 579.10K | 479.40K | 690.40K |
| Operating Income | -392.40K | -680.90K | -579.10K | -479.40K | -690.40K |
| Income Before Tax | -1.69M | -808.50K | -590.50K | -649.50K | -717.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.69M | -808.50K | -590.50K | -649.50K | -717.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.69M | -808.50K | -590.50K | -649.50K | -717.70K |
| EBIT | -392.40K | -680.90K | -579.10K | -479.40K | -690.40K |
| EBITDA | -388.70K | -677.00K | -572.00K | -472.00K | -662.70K |
| EPS Basic | -1.05 | -0.58 | -0.45 | -0.67 | -0.95 |
| Normalized Basic EPS | -0.65 | -0.36 | -0.28 | -0.42 | -0.59 |
| EPS Diluted | -1.05 | -0.58 | -0.45 | -0.67 | -0.95 |
| Normalized Diluted EPS | -0.65 | -0.36 | -0.28 | -0.42 | -0.59 |
| Average Basic Shares Outstanding | 1.62M | 1.39M | 1.31M | 971.30K | 757.60K |
| Average Diluted Shares Outstanding | 1.62M | 1.39M | 1.31M | 971.30K | 757.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |